Jigsaw Medical

jigsawmedical.com

Founded in 2012 by Chris Percival, Jigsaw Medical has quickly become one of the UK leaders in medical services, offering a range of services for the commercial, media, events sectors and the NHS. Jigsaw Medical is divided into three clear entities; our Clinical Services Division, Training Division, and our Specialist Projects Division. We are committed to delivering clinically focused and harmonised solutions to both NHS and private clients. Our Clinical Services Division specialises in providing ambulance services, event medical cover, and TV / Film unit medics whilst our Training Division provides first aid training courses and clinical education. Finally, our Special Projects Division provides specific medical training and medical staff for close protection, hostile, and remote environments – making up our four clear divisions.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

BIOCLINICA ANNOUNCES THAT IT WILL LEVERAGE BIOCLINICA'S INTERACTIVE RESPONSE TECHNOLOGY (IRT) FOR THEIR EXIT COVID-19 STUDY

Bioclinica | September 10, 2020

news image

Bioclinica, an integrated solutions provider of clinical life science and technology expertise, delivering powerful insight into clinical trial development in bringing new therapies to people worldwide, announced today that Direct Biologics, a market leading innovator and science-based manufacturer of regenerative products, will leverage Bioclinica's Interactive Response Technology (IRT) for their EXIT COVID-19 study — a multi-center FDA phase II clinical trial for the use of ExoFlo&tr...

Read More

AFTER CLOSING ONE OF CHINA'S BIGGEST-EVER RAISES, I-MAB BIOPHARMA NABS $104M NASDAQ IPO

FierceBiotech | January 17, 2020

news image

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite. It hit $14 a share, the midpoint in the range, and becomes the first Chinese biotech in more than two years (the last being Zai Lab back in 2017) to gain a U.S. IPO. According to recent reports out of Bloomberg, however, it had been quietly hoping for a $200 million offering. The offering seems relatively tame after the monster raises it has gained over the years, including $22...

Read More

Industrial Impact, Medical

OMEGA THERAPEUTICS ANNOUNCES CLINICAL SUPPLY AGREEMENT TO EVALUATE THE COMBINATION OF OTX-2002 AND ATEZOLIZUMAB IN HEPATOCELLULAR CARCINOMA

Globenewswire | March 31, 2023

news image

Omega Therapeutics, Inc. a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenetic mRNA medicines, today announced a clinical supply agreement with Roche to evaluate OTX-2002, its lead candidate in development for the treatment of MYC-driven hepatocellular carcinoma (HCC), in combination with Roche’s anti-PD-L1 therapy, atezolizumab, as part of Omega’s Phase 1/2 MYCHELANGELO™ I clinical trial. “This agreem...

Read More

Industrial Impact

PORTAL INNOVATIONS EXPANDS CHICAGO OPERATIONS TRIPLES SPACE IN FULTON LABS

Portal Innovations | February 03, 2022

news image

Portal Innovations continues its momentum in Chicago by launching the second phase of its operations with the opening of 35,000 square feet of premier wet and dry lab and office space at 400 North Aberdeen in Fulton Labs. The new facility will allow Portal, a life sciences venture development engine, to grow and scale its investment in early-stage biotech companies in Chicago. Portal has tapped Patrick Flavin to serve as President of its flagship Chicago operation. With over 20 ye...

Read More
news image

BIOCLINICA ANNOUNCES THAT IT WILL LEVERAGE BIOCLINICA'S INTERACTIVE RESPONSE TECHNOLOGY (IRT) FOR THEIR EXIT COVID-19 STUDY

Bioclinica | September 10, 2020

Bioclinica, an integrated solutions provider of clinical life science and technology expertise, delivering powerful insight into clinical trial development in bringing new therapies to people worldwide, announced today that Direct Biologics, a market leading innovator and science-based manufacturer of regenerative products, will leverage Bioclinica's Interactive Response Technology (IRT) for their EXIT COVID-19 study — a multi-center FDA phase II clinical trial for the use of ExoFlo&tr...

Read More
news image

AFTER CLOSING ONE OF CHINA'S BIGGEST-EVER RAISES, I-MAB BIOPHARMA NABS $104M NASDAQ IPO

FierceBiotech | January 17, 2020

China-based cancer and autoimmune disease biotech I-Mab Biopharma has raised $104 million on the U.S. Nasdaq composite. It hit $14 a share, the midpoint in the range, and becomes the first Chinese biotech in more than two years (the last being Zai Lab back in 2017) to gain a U.S. IPO. According to recent reports out of Bloomberg, however, it had been quietly hoping for a $200 million offering. The offering seems relatively tame after the monster raises it has gained over the years, including $22...

Read More
news image

Industrial Impact, Medical

OMEGA THERAPEUTICS ANNOUNCES CLINICAL SUPPLY AGREEMENT TO EVALUATE THE COMBINATION OF OTX-2002 AND ATEZOLIZUMAB IN HEPATOCELLULAR CARCINOMA

Globenewswire | March 31, 2023

Omega Therapeutics, Inc. a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenetic mRNA medicines, today announced a clinical supply agreement with Roche to evaluate OTX-2002, its lead candidate in development for the treatment of MYC-driven hepatocellular carcinoma (HCC), in combination with Roche’s anti-PD-L1 therapy, atezolizumab, as part of Omega’s Phase 1/2 MYCHELANGELO™ I clinical trial. “This agreem...

Read More
news image

Industrial Impact

PORTAL INNOVATIONS EXPANDS CHICAGO OPERATIONS TRIPLES SPACE IN FULTON LABS

Portal Innovations | February 03, 2022

Portal Innovations continues its momentum in Chicago by launching the second phase of its operations with the opening of 35,000 square feet of premier wet and dry lab and office space at 400 North Aberdeen in Fulton Labs. The new facility will allow Portal, a life sciences venture development engine, to grow and scale its investment in early-stage biotech companies in Chicago. Portal has tapped Patrick Flavin to serve as President of its flagship Chicago operation. With over 20 ye...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us